{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T07:12:58Z","timestamp":1779347578156,"version":"3.51.4"},"reference-count":28,"publisher":"e-Century Publishing Corporation","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/nhdl1532","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T08:50:56Z","timestamp":1764924656000},"page":"8973-8984","source":"Crossref","is-referenced-by-count":0,"title":["Belimumab combined with mycophenolate mofetil for treating severe lupus nephritis: effects on renal recovery, immune regulation, and long-term prognosis"],"prefix":"10.62347","volume":"17","author":[{"given":"Jiaying","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1016\/S0140-6736(24)00398-2","article-title":"Systemic lupus erythematosus","volume":"403","author":"Hoi","year":"2024","unstructured":"Hoi A, Igel T, Mok CC and Arnaud L. Systemic lupus erythematosus. Lancet 2024; 403: 2326-2338.","journal-title":"Lancet"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s11684-021-0849-2","article-title":"Mycophenolate mofetil or tacrolimus compared with azathioprine in long-term maintenance treatment for active lupus nephritis","volume":"16","author":"Zhang","year":"2022","unstructured":"Zhang Q, Xing P, Ren H, Chen X, Xie J, Zhang W, Shen P, Li X and Chen N. Mycophenolate mofetil or tacrolimus compared with azathioprine in long-term maintenance treatment for active lupus nephritis. Front Med 2022; 16: 799-807.","journal-title":"Front Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and safety of obinutuzumab in active lupus nephritis","volume":"392","author":"RA","year":"2025","unstructured":"Furie RA, Rovin BH, Garg JP, Santiago MB, Aroca-Martínez G, Zuta Santillán AE, Alvarez D, Navarro Sandoval C, Lila AM, Tumlin JA, Saxena A, Irazoque Palazuelos F, Raghu H, Yoo B, Hassan I, Martins E, Sehgal H, Kirchner P, Ross Terres J, Omachi TA, Schindler T, Pendergraft WF 3rd and Malvar A; REGENCY Trial Investigators. Efficacy and safety of obinutuzumab in active lupus nephritis. N Engl J Med 2025; 392: 1471-1483.","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Teoh STY, Yap DYH, Yung S and Chan TM. Lupus Nephritis and chronic kidney disease: a scoping review. Nephrology (Carlton) 2025; 30: e14427.","DOI":"10.1111\/nep.14427"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Tselios K, Gladman DD, Su J and Urowitz MB. Advanced chronic kidney disease in lupus nephritis: is dialysis inevitable? J Rheumatol 2020; 47: 1366-1373.","DOI":"10.3899\/jrheum.191064"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1177\/09612033241228177","article-title":"Comparison of efficacy of continuous mycophenolate mofetil with sequential cyclophosphamide and tacrolimus as maintenance therapy for lupus nephritis","volume":"33","author":"Kawazoe","year":"2024","unstructured":"Kawazoe M and Nanki T. Comparison of efficacy of continuous mycophenolate mofetil with sequential cyclophosphamide and tacrolimus as maintenance therapy for lupus nephritis. Lupus 2024; 33: 319-327.","journal-title":"Lupus"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/art.41466","article-title":"Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis","volume":"73","author":"Atisha-Fregoso Y","year":"2021","unstructured":"Atisha-Fregoso Y, Malkiel S, Harris KM, Byron M, Ding L, Kanaparthi S, Barry WT, Gao W, Ryker K, Tosta P, Askanase AD, Boackle SA, Chatham WW, Kamen DL, Karp DR, Kirou KA, Sam Lim S, Marder B, McMahon M, Parikh SV, Pendergraft WF 3rd, Podoll AS, Saxena A, Wofsy D, Diamond B, Smilek DE, Aranow C and Dall’Era M. Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthritis Rheumatol 2021; 73: 121-131.","journal-title":"Arthritis Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2072143","DOI":"10.1080\/21645515.2022.2072143","article-title":"Belimumab for systemic lupus erythematosus - Focus on lupus nephritis","volume":"18","author":"Pl&#xFC","year":"2022","unstructured":"Plüß M, Piantoni S, Tampe B, Kim AHJ and Korsten P. Belimumab for systemic lupus erythematosus - Focus on lupus nephritis. Hum Vaccin Immunother 2022; 18: 2072143.","journal-title":"Hum Vaccin Immunother"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"de la Rubia Navarro M, Ivorra Cortés JR, Grau García E and Román Ivorra JA. Efectiveness of belimumab in the treatment of lupus nephritis: analysis of 8 cases. Med Clin (Barc) 2022; 159: 344-346.","DOI":"10.1016\/j.medcle.2022.05.013"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s12016-023-08963-3","article-title":"Perspectives on mycophenolate mofetil in the management of autoimmunity","volume":"65","author":"Bhat","year":"2023","unstructured":"Bhat R, Tonutti A, Timilsina S, Selmi C and Gershwin ME. Perspectives on mycophenolate mofetil in the management of autoimmunity. Clin Rev Allergy Immunol 2023; 65: 86-100.","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Slight-Webb S, Guthridge JM, Chakravarty EF, Chen H, Lu R, Macwana S, Bean K, Maecker HT, Utz PJ and James JA. Mycophenolate mofetil reduces STAT3 phosphorylation in systemic lupus erythematosus patients. JCI Insight 2019; 4: e124575.","DOI":"10.1172\/jci.insight.124575"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13075-023-03089-5","article-title":"Deconvolution of whole blood transcriptomics identifies changes in immune cell composition in patients with systemic lupus erythematosus (SLE) treated with mycophenolate mofetil","volume":"25","author":"Akthar","year":"2023","unstructured":"Akthar M, Nair N, Carter LM, Vital EM, Sutton E, McHugh N; British Isles Lupus Assessment Group Biologics Register (BILAG BR) Consortium; MASTERPLANS Consortium, Bruce IN and Reynolds JA. Deconvolution of whole blood transcriptomics identifies changes in immune cell composition in patients with systemic lupus erythematosus (SLE) treated with mycophenolate mofetil. Arthritis Res Ther 2023; 25: 111.","journal-title":"Arthritis Res Ther"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/mrcr\/rxab020","article-title":"Effect of a multitarget therapy with prednisolone, mycophenolate mofetil, and tacrolimus in a patient with type B insulin resistance syndrome complicated by lupus nephritis","volume":"6","author":"Temmoku","year":"2022","unstructured":"Temmoku J, Asano T, Saito K, Matsumoto H, Fujita Y, Furuya-Yashiro M, Matsuoka N, Oda A, Tanabe H, Sato S, Shio-Yano K, Sasajima T, Kiko Y, Kobayashi H, Watanabe H, Shimabukuro M and Migita K. Effect of a multitarget therapy with prednisolone, mycophenolate mofetil, and tacrolimus in a patient with type B insulin resistance syndrome complicated by lupus nephritis. Mod Rheumatol Case Rep 2022; 6: 41-46.","journal-title":"Mod Rheumatol Case Rep"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"You Y, Zhou Z, Wang F, Li J, Liu H, Cheng X, Su Y, Chen X, Zheng H, Sun Y, Shi H, Hu Q, Xu J, Teng J, Yang C and Ye J. Mycophenolate mofetil and new-onset systemic lupus erythematosus: a randomized clinical trial. JAMA Netw Open 2024; 7: e2432131.","DOI":"10.1001\/jamanetworkopen.2024.32131"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Yu X, Chen N, Xue J, Mok CC, Bae SC, Peng X, Chen W, Ren H, Li X, Noppakun K, Gilbride JA, Green Y, Ji B, Liu C, Madan A, Okily M, Tang CH and Roth DA. Efficacy and safety of belimumab in patients with lupus nephritis: subgroup analyses of a phase 3 randomized trial in the east Asian population. Am J Kidney Dis 2023; 81: 294-306, e1.","DOI":"10.1053\/j.ajkd.2022.06.013"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.5114\/reum\/190257","article-title":"Usefulness in daily practice of the systemic lupus erythematosus disease activity index 2000 scale and the systemic lupus erythematosus disease activity score index for assessing the activity of systemic lupus erythematosus","volume":"62","author":"Suszek","year":"2024","unstructured":"Suszek D, Dubaj M, Bigosiński K, Dembowska A, Kaniewski M, Sielwanowska W, Skierkowski B, Dzikowska I, Sieczka J and Majdan M. Usefulness in daily practice of the systemic lupus erythematosus disease activity index 2000 scale and the systemic lupus erythematosus disease activity score index for assessing the activity of systemic lupus erythematosus. Reumatologia 2024; 62: 187-195.","journal-title":"Reumatologia"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, Boletis J, Bruce IN, Cervera R, Doria A, Dörner T, Furie RA, Gladman DD, Houssiau FA, Inês LS, Jayne D, Kouloumas M, Kovács L, Mok CC, Morand EF, Moroni G, Mosca M, Mucke J, Mukhtyar CB, Nagy G, Navarra S, Parodis I, Pego-Reigosa JM, Petri M, Pons-Estel BA, Schneider M, Smolen JS, Svenungsson E, Tanaka Y, Tektonidou MG, Teng YO, Tincani A, Vital EM, van Vollenhoven RF, Wincup C, Bertsias G and Boumpas DT. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024; 83: 15-29.","journal-title":"Ann Rheum Dis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1093\/ndt\/gfaa117","article-title":"Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results","volume":"36","author":"Kraaij","year":"2021","unstructured":"Kraaij T, Arends EJ, van Dam LS, Kamerling SWA, van Daele PLA, Bredewold OW, Ray A, Bakker JA, Scherer HU, Huizinga TJW, Rabelink TJ, van Kooten C and Teng YKO. Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results. Nephrol Dial Transplant 2021; 36: 1474-1483.","journal-title":"Nephrol Dial Transplant"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"102729","DOI":"10.1016\/j.jaut.2021.102729","article-title":"Results from a large, nationwide, multicentric cohort","volume":"124","author":"Gatto","year":"2021","unstructured":"Gatto M, Saccon F, Andreoli L, Bartoloni E, Benvenuti F, Bortoluzzi A, Bozzolo E, Brunetta E, Canti V, Cardinaletti P, Ceccarelli F, Ciccia F, Conti F, De Marchi G, de Paulis A, De Vita S, Emmi G, Faggioli P, Fasano S, Fredi M, Gabrielli A, Gasparotto M, Gerli R, Gerosa M, Govoni M, Gremese E, Laria A, Larosa M, Mosca M, Orsolini G, Pazzola G, Petricca L, Ramirez GA, Regola F, Rossi FW, Rossini M, Salvarani C, Scarpato S, Tani C, Tincani A, Ubiali T, Urban ML, Zen M, Doria A and Iaccarino L. Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort. J Autoimmun 2021; 124: 102729.","journal-title":"J Autoimmun"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"7627","DOI":"10.3390\/jcm12247627","article-title":"Real-world effectiveness of belimumab in patients with active lupus","volume":"12","author":"Sumichika","year":"2023","unstructured":"Sumichika Y, Yoshida S, Suzuki E, Saito K, Matsumoto H, Temmoku J, Fujita Y, Matsuoka N, Asano T, Sato S and Migita K. Real-world effectiveness of belimumab in patients with active lupus. J Clin Med 2023; 12: 7627.","journal-title":"J Clin Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"103369","DOI":"10.1016\/j.jaut.2025.103369","article-title":"CAR-T cell targeting three receptors on autoreactive B cells for systemic lupus erythematosus therapy","volume":"151","author":"Uppin","year":"2025","unstructured":"Uppin V, Gibbons H, Troje M, Feinberg D, Webber BR, Moriarity BS and Parameswaran R. CAR-T cell targeting three receptors on autoreactive B cells for systemic lupus erythematosus therapy. J Autoimmun 2025; 151: 103369.","journal-title":"J Autoimmun"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1002\/hep4.1559","article-title":"Targeted inhibition of purine metabolism is effective in suppressing hepatocellular carcinoma progression","volume":"4","author":"Chong","year":"2020","unstructured":"Chong YC, Toh TB, Chan Z, Lin QXX, Thng DKH, Hooi L, Ding Z, Shuen T, Toh HC, Dan YY, Bonney GK, Zhou L, Chow P, Wang Y, Benoukraf T, Chow EK and Han W. Targeted inhibition of purine metabolism is effective in suppressing hepatocellular carcinoma progression. Hepatol Commun 2020; 4: 1362-1381.","journal-title":"Hepatol Commun"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Struemper H, Kurtinecz M, Edwards L, Freimuth WW, Roth DA and Stohl W. Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE. Lupus Sci Med 2022; 9: e000499.","DOI":"10.1136\/lupus-2021-000499"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"796508","DOI":"10.3389\/fimmu.2022.796508","article-title":"Early B cell and plasma cell kinetics upon treatment initiation portend flares in systemic lupus erythematosus: a post-hoc analysis of three phase iii clinical trials of belimumab","volume":"13","author":"Parodis","year":"2022","unstructured":"Parodis I, Gomez A, Chow JW, Borg A, Lindblom J and Gatto M. Early B cell and plasma cell kinetics upon treatment initiation portend flares in systemic lupus erythematosus: a post-hoc analysis of three phase iii clinical trials of belimumab. Front Immunol 2022; 13: 796508.","journal-title":"Front Immunol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1080\/14712598.2021.1895744","article-title":"Belimumab: a step forward in the treatment of systemic lupus erythematosus","volume":"21","author":"Depascale","year":"2021","unstructured":"Depascale R, Gatto M, Zen M, Saccon F, Larosa M, Zanatta E, Bindoli S, Doria A and Iaccarino L. Belimumab: a step forward in the treatment of systemic lupus erythematosus. Expert Opin Biol Ther 2021; 21: 563-573.","journal-title":"Expert Opin Biol Ther"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1177\/09612033221119123","article-title":"Efficacy and safety of belimumab in systemic lupus erythematosus patients with severe lupus nephritis requiring renal replacement therapy","volume":"31","author":"Liu","year":"2022","unstructured":"Liu D, Zhou Q, Wang D, Qu Y, Guo Q, Wen J, Yu Q and Ai J. Efficacy and safety of belimumab in systemic lupus erythematosus patients with severe lupus nephritis requiring renal replacement therapy. Lupus 2022; 31: 1456-1467.","journal-title":"Lupus"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"631","DOI":"10.12659\/MSM.899973","article-title":"Urinary albumin levels are independently associated with renal lesion severity in patients with lupus nephritis and little or no proteinuria","volume":"23","author":"Ding","year":"2017","unstructured":"Ding J, Zheng Z, Li X, Feng Y, Leng N, Wu Z and Zhu P. Urinary albumin levels are independently associated with renal lesion severity in patients with lupus nephritis and little or no proteinuria. Med Sci Monit 2017; 23: 631-639.","journal-title":"Med Sci Monit"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s11255-021-02873-z","article-title":"Relationship between hyperuricemia and serositis in patients with lupus nephritis","volume":"54","author":"Nie","year":"2022","unstructured":"Nie P, Hu L, Li B, Lou Y, Luo M, Wang Y, Lu X and Luo P. Relationship between hyperuricemia and serositis in patients with lupus nephritis. Int Urol Nephrol 2022; 54: 357-364.","journal-title":"Int Urol Nephrol"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/11\/ajtr0165876.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T06:51:06Z","timestamp":1779346266000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/11\/ajtr0165876.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":28,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/nhdl1532","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}